Literature DB >> 19643863

Video-assisted surgery for lung cancer. State of the art and personal experience.

Jesus Loscertales1, Rafael Jimenez-Merchan, Miguel Congregado, Francisco Javier Ayarra, Gregorio Gallardo, Ana Triviño.   

Abstract

This paper reviews the role of videothoracoscopy in lung cancer, highlighting its utility in definitive staging, diagnosis, and treatment. We show exploratory videothoracoscopy to be the perfect technique for last-minute staging, looking for tumor invasion, especially parietal T3 and vascular T4 (due to videopericardioscopy), management of solitary pulmonary nodules, and the possibility of radical treatment with video-assisted thoracoscopic lobectomy. We perform an overview of the literature and analyze our experience of 1,381 patients with lung cancer. In 1,277 of them, the final decision on resectability was made by exploratory videothoracoscopy, including 91 by videopericardioscopy (only 30 were considered non-resectable on videopericardioscopy). Solitary pulmonary nodules were diagnosed in 382 cases (190 were cancer), and we performed 260 major lung resections by video-assisted thoracoscopic surgery (22 pneumonectomies, 238 lobectomies/bilobectomies).

Entities:  

Mesh:

Year:  2009        PMID: 19643863     DOI: 10.1177/0218492309104747

Source DB:  PubMed          Journal:  Asian Cardiovasc Thorac Ann        ISSN: 0218-4923


  2 in total

1.  Multidisciplinary consensus statement on the clinical management of patients with stage III non-small cell lung cancer.

Authors:  M Majem; J Hernández-Hernández; F Hernando-Trancho; N Rodríguez de Dios; A Sotoca; J C Trujillo-Reyes; I Vollmer; R Delgado-Bolton; M Provencio
Journal:  Clin Transl Oncol       Date:  2019-06-06       Impact factor: 3.405

2.  Video-assisted thoracic surgery lobectomy: results in lung cancer.

Authors:  Jesús Loscertales; Florencio Quero Valen Zuela; Miguel Congregado; Rafael Jiménez Merchán; Gregorio Gallardo Varela; Ana Trivino Ramírez; Sergio B Moreno Merino; Fernando Cózar Bernal
Journal:  J Thorac Dis       Date:  2010-03       Impact factor: 2.895

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.